Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Current Liabilities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Current Liabilities for 4 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 5.28% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 5.28% decrease, with the full-year FY2024 number at $3.1 million, up 38.13% from a year prior.
  • Total Current Liabilities was $2.4 million for Q3 2025 at bioAffinity Technologies, down from $2.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $3.4 million in Q1 2025 to a low of $775151.0 in Q2 2023.
  • A 4-year average of $2.0 million and a median of $2.2 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 200.11% in 2024, then decreased 5.28% in 2025.
  • bioAffinity Technologies' Total Current Liabilities stood at $1.1 million in 2022, then soared by 97.41% to $2.2 million in 2023, then skyrocketed by 38.13% to $3.1 million in 2024, then dropped by 24.0% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Total Current Liabilities are $2.4 million (Q3 2025), $2.6 million (Q2 2025), and $3.4 million (Q1 2025).